BioCentury | Jan 15, 2021

A maturing mid-cap sector could keep funds flowing into biotech

While it’s too early to say whether 2020’s record year of fund-raising constitutes a “new normal,” there’s consensus among buysiders and bankers that a cheap money environment will continue in 2021 as...
BioCentury | Nov 7, 2020

Galapagos gains new antifibrotic mechanism through OncoArendi deal

Galapagos’ latest move to expand its early fibrosis pipeline, via a deal with Polish biotech OncoArendi, gives the company access to a new fibrosis-blocking immune mechanism.  Through the exclusive collaboration and licensing agreement, Galapagos N.V....
BioCentury | Aug 26, 2020

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

...which brings the company’s total funding to more than $71 million. New investors Eagle Fund SP1...
BioCentury | Jul 30, 2020
Product Development

Sanofi, AZ pave the way for new RSV mAb with long-lasting protection data

Sanofi and AstraZeneca are on track to deliver an RSV-preventing mAb that would be more accessible and possibly more effective than Synagis in infants. In a New England Journal of Medicine paper published on Wednesday,...
BioCentury | Jul 10, 2020

With record fund flows, biotech a top sector for investors heading into 3Q20

Investors expect the massive inflows to biotech to continue over the next quarter as the sector is viewed as a top defensive pick in a struggling global economy that is unlikely to improve until the...
BioCentury | Jun 12, 2020

June 11 Quick Takes: Biotech swept up in sell-off; plus Simcere, Lantern, Cue Health, C2i, BaseLaunch, Sanofi-Cathay and 4BIO

Biotech tumbles as U.S. indexes plunge Biotech indexes fell along with the broader markets Thursdays in a sell-off sparked by fears of an increase in COVID-19 infections. The NASDAQ Composite, S&P 500 and Dow Jones...
BioCentury | May 12, 2020

NBI hits all-time high as biotech stocks surge

The NASDAQ Biotechnology Index rose 168.42, or 4%, to 4,201.88 on Monday, reaching an all-time high on the back of substantial inflows into the sector. Twenty-eight companies gained double-digit percentage points as the NBI breached...
BioCentury | May 8, 2020

Follow-on market poised for comeback, at least temporarily

Pandemic-driven market volatility has stymied follow-on activity the past two months, but stabilizing markets and big inflows are opening a window of opportunity, at least in the near term. The unfolding consequences of COVID-19 could...
BioCentury | May 1, 2020

As market’s upbeat April draws to close, Lyra becomes latest biotech IPO to surge

Lyra became the latest biotech to gain value after pricing its IPO at the top of its range, signaling continued strength among the sector’s new listings in a season of volatility. The ear, nose and...
BioCentury | Apr 9, 2020

Keros rises 26% in trading debut during week of market gains

Keros priced an upsized IPO Wednesday and gained $4.08 (26%) to $20.08 despite continued pandemic-driven volatility in the markets. While the Arca NYSE Biotechnology (BTK) and NASDAQ Biotechnology (NBI) and the S&P Biotech ETF (XBI)...
Items per page:
1 - 10 of 804